TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation

Leuven (BELGIUM) - 1 September, 2014 -TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has appointed Dr Marie Paule Richard as the Company's Chief Medical Officer, and Dr Mary Carmen Diez as its Vice President Medical Affairs and New Product Commercialisation.

Dr Richard is an immunologist with more than 25 years experience in the global biopharmaceutical industry, including Chief Medical Officer at Aicuris in Germany; Vice President, Clinical Development, Pharmacovigilance and Medical Affairs at Crucell in Switzerland; and Vice President Vaccines Clinical Development at Sanofi Pasteur in France. She has successfully led the development and regulatory approval of several products both in Europe and in the United States. As Chief Medical Officer at TiGenix, Dr Richard will be responsible for the development of Cx611 in both early rheumatoid arthritis and severe sepsis, for the completion of the ongoing European pivotal Phase III trial with Cx601 in complex perianal fistulas in Crohn's disease, and for the preparation and implementation of the development plan of Cx601 in the United States.

Dr Diez, a medical doctor specialised in Internal Medicine and Infectious Diseases, has more than 20 years experience in the biopharmaceutical industry. She joins from Meda Pharma, where she was International Medical Marketing Director for the last nine years. She has been responsible for the preparation and execution of the successful on-time launch of several products at European level. Prior to that, she worked for a number of pharmaceutical companies including Asta Médica, Pfizer and Dupont Pharma. As Vice President, Medical Affairs and New Product Commercialisation, Dr Diez will be responsible for the medical affairs function across all the Company's assets and, more importantly, she will be directly in charge of preparations for the launch of Cx601 in Europe.

"The whole focus of TiGenix is now the successful clinical development, regulatory approval and future commercialisation of the new products in its development pipeline," said Eduardo Bravo, Chief Executive Officer of TiGenix. "It is therefore essential that we build the capability to do that well. We are very fortunate to have two biopharma development, regulatory and commercialisation heavyweights in Marie Paule and Mary Carmen joining the TiGenix management team at this point in time. They bring with them a wealth of experience and ability in areas which will be key for the success of the company in the near future: namely, completing the development of Cx601 in Europe and in the US, gaining regulatory approval and preparing for its launch, and guiding the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis."

For more information

Richard Simpson
Senior Consultant, Comfi sprl
T: +32 494 578 278
richard@comfi.be